Prognostic Stage 2 Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Prognostic Stage II Breast Cancer AJCC v8

DBCOND0140767 (Prognostic Stage 2 Breast Cancer AJCC v8)Not Yet Recruiting1 IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment